Tamoxifen combined to anti-HER-2/neu cell vaccine does not hamper cancer immunopreventive efficacy.
The possible interference of tamoxifen with anti-tumor vaccines was studied in a translational view of combined preventive approaches. Tamoxifen treatment of HER-2/neu transgenic mice combined to anti-HER-2/neu cell vaccine did not hamper the efficacy of cancer immunoprevention, and caused a significantly increased production of interferon-gamma. These data suggest that tamoxifen could even have a positive impact on the efficacy of cancer immunoprevention.
De Giovanni
Carla
C
Department of Experimental Pathology, Alma Mater Studiorum - University of Bologna, Viale Filopanti 22, I-40126 Bologna, Italy. carla.degiovanni@unibo.it
Nicoletti
Giordano
G
Landuzzi
Lorena
L
Croci
Stefania
S
Palladini
Arianna
A
Antognoli
Agnese
A
Murgo
Annalisa
A
Ianzano
Marianna L
ML
Grosso
Valentina
V
Stivani
Valeria
V
Iezzi
Manuela
M
Musiani
Piero
P
Nanni
Patrizia
P
Lollini
Pier-Luigi
PL
D000818:Animals; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use*; D002277:Carcinoma / Q000276:immunology / Q000517:prevention & control*; D002478:Cells, Cultured; D003131:Combined Modality Therapy; D005260:Female; D018734:Genes, erbB-2 / Q000235:genetics / Q000276:immunology*; D007371:Interferon-gamma / Q000096:biosynthesis; D008325:Mammary Neoplasms, Experimental / Q000276:immunology / Q000517:prevention & control*; D051379:Mice; D008822:Mice, Transgenic; D013154:Spleen / Q000276:immunology / Q000378:metabolism; D013629:Tamoxifen / Q000627:therapeutic use*; D014611:Vaccination
D018931:Antineoplastic Agents, Hormonal; D019496:Cancer Vaccines; D013629:Tamoxifen; D007371:Interferon-gamma